Across TCGA pan-cancer cohorts, LORICRIN Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LORICRIN data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher LORICRIN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LORICRIN expression acts as an unfavorable survival marker.

ESCA are the cancer types where LORICRIN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.141	0.525	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LORICRIN tumor-vs-normal RNA expression · all LORICRIN data types